Quick Read
Seventy percent of Wall Street analysts remain bullish on GE HealthCare (GEHC) after a guidance cut that sent shares to a 52-week low.
One segment lost nearly all of its profit in a single quarter. Even so, the company’s order backlog tells a completely different story about where demand is actually headed.
The analyst who called NVIDIA in 2010 just named his top 10 stocks and GE HealthCare wasn’t one of them. Get them here FREE.
GE HealthCare (NASDAQ: GEHC) currently trades at $59.49, well below the Wall Street consensus price target of $89.74. That implies upside of roughly 50.8% if the analysts are right.
GE HealthCare is the medical imaging and diagnostics business spun from General Electric, with about $20.6 billion in annual revenue across Advanced Imaging Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics. Wall Street has treated it as a defensive growth story tied to aging demographics, hospital capex, and a refresh cycle in CT and MRI hardware.
The company just snapped its multi-quarter beat streak and management trimmed full-year profit guidance. The market reaction was severe enough to break the prior 52-week low, raising the question of whether this is a real rerating or an overreaction to a temporary problem.
The analyst who called NVIDIA in 2010 just named his top 10 stocks and GE HealthCare wasn’t one of them. Get them here FREE.
A 13% Single-Day Drop on a Margin Guide-Down
The catalyst for the decline was the guidance cut. GE HealthCare reduced its full-year 2026 adjusted EPS range to $4.80 to $5.00, down from $4.95 to $5.15, and lowered free cash flow guidance to roughly $1.6 billion from $1.7 billion. Adjusted EBIT margin guidance fell to 15.4% to 15.7%. Shares fell 13.2% on the day.
That reaction is outsized. Across the prior four reports, the average day-of move was −0.55%. Q1 adjusted EPS landed at $0.99 against $1.05 consensus, a 5.71% miss, while revenue beat at $5.13 billion, up 7.41% year over year. Adjusted EBIT margin contracted 150 basis points to 13.5%.
Two issues drove the profit miss. CEO Peter Arduini cited “a PDx supplier issue that has since been resolved” and “significant increases in memory chips, oil and freight costs” that management expects to persist. Patient Care Solutions revenue fell 6.5% and segment EBIT collapsed 79.8% to just $10 million.
Why the Sell Side Is Sticking With the Bull Case
With implied upside above 50%, the analyst stance merits scrutiny. Of 19 covering analysts, three rate it Strong Buy, 10 at Buy, five Hold, and one Underperform. Sentiment skews about 70% bullish to 5% bearish. The core thesis is that cost shocks are macro-driven rather than structural, and the topline engine remains intact.
